[Combined effects of arbekacin with biapenem against in vitro and in vivo model of a mixture of MRSA and Pseudomonas aeruginosa].
Combined effects of arbekacin (ABK) with biapenem (BIPM) were examined on both in vitro and in vivo model of a mixture of MRSA and Pseudomonas aeruginosa. As a result, significant effect in vitro was observed in combined use of ABK (1/2 MIC) with BIPM (1/4 and 1/2 MIC) against MRSA as compared with ABK or BIPM alone. Against P. aeruginosa combined effect was also observed, showing reduction of viable cells to the limitation of detection within 2 hours. Moreover, with respect to the protective effect on mixed systemic infection of MRSA and P. aeruginosa, the combined treatment with ABK and BIPM showed more excellent efficacy as compared with the single use of each drug.
Niida
Masashi
M
Infectious Disease Research Laboratory, Meiji Seika Kaisha, Ltd. 760 Morooka-cho, Kohoku-ku, Yokohama 222-8567, Japan.
Sakakibara
Shirou
S
Kawabata
Toshie
T
Maebashi
Kazunori
K
Takata
Toshihiko
T
Hikida
Muneo
M
D000617:Aminoglycosides / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology*; D003982:Dibekacin / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004338:Drug Combinations; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D008297:Male; D016106:Methicillin Resistance; D051379:Mice; D008813:Mice, Inbred ICR; D011552:Pseudomonas Infections / Q000150:complications* / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D013203:Staphylococcal Infections / Q000150:complications* / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*; D013845:Thienamycins / Q000494:pharmacology* / Q000627:therapeutic use*
D000617:Aminoglycosides; D000890:Anti-Infective Agents; D004338:Drug Combinations; D013845:Thienamycins; D003982:Dibekacin; C031986:arbekacin; C065257:biapenem